

Substitute for form 1449B/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Application Number	10/785,374
Filing Date	February 24, 2004
First Named Inventor	Summar et al.
Art Unit	1638
Examiner Name	D. Johannsen

Sheet

1

of

2

Attorney Docket Number 1242/58 CIP

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Aschner, J. L., "New Therapies for Pulmonary Hypertension in Neonates and Children," <i>Pediatr. Pulmonol. Suppl.</i> , Vol. 26, pgs. 132-135 (2004).	
	2	Blum et al., "Oral L-arginine in Patients with Coronary Artery Disease on Medical Management," <i>Circulation</i> , Vol. 101, pgs. 2160-2164 (May 9, 2000).	
	3	Chin-Dusting et al., "Dietary supplementation with L-arginine fails to restore endothelial function in forearm resistance arteries of patients with severe heart failure," <i>J. Am. Coll. Cardiol.</i> , Vol. 27, pgs. 1207-1213 (1996).	
	4	Feng et al., "Effects of L-arginine on endothelial and cardiac function in rats with heart failure," <i>Eur. J. Pharmacol.</i> , Vol. 376, pgs. 37-44 (July 2, 1999).	
	5	Hladunewich et al., "Effect of L-arginine therapy on the glomerular injury of preeclampsia: a randomized controlled trial," <i>Obstet. Gynecol.</i> , Vol. 107, pgs. 886-895 (2006).	
	6	Laursen et al., "Hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy is unaltered by long-term oral L-arginine administration," <i>Vascul. Pharmacol.</i> , Vol. 49, pgs. 71-76 (2008).	
	7	Lorentz et al., "Modulation of systemic hemodynamics by exogenous L-arginine in normal and bacteremic sheep," <i>Crit. Care Med.</i> , Vol. 27, pgs. 2474-2479 (1999).	
	8	Miller et al., "Effects of an acute dose of L-arginine during coronary angiography in patients with chronic renal failure: a randomized, parallel, double-blind clinical trial," <i>Am. J. Nephrol.</i> , Vol. 23, pgs. 91-95 (2003).	
	9	Morris et al., "Hydroxyurea and arginine therapy: impact on nitric oxide production in sickle cell disease," <i>J. Pediatr. Hematol. Oncol.</i> , Vol. 25, pgs. 629-634 (2003).	
	10	Paulus et al., "Myocardial contractile effects of L-arginine in the human allograft," <i>J. Am. Coll. Cardiol.</i> , Vol. 29, pgs. 1332-1338 (1997).	
	11	Romero et al., "Therapeutic use of citrulline in cardiovascular disease," <i>Cardiovasc. Drug Rev.</i> , Vol. 24, pgs. 275-290 (2006).	

Examiner Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Do not include copy of this form with next communication to applicant.

Applicants under a claim of domestic priority to a U.S. nonprovisional application, please place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is retained to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<p>Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.</p> <p>Substitute for form 1449B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(Use as many sheets as necessary)</p>			
		Complete if Known	
Application Number		10/785,374	
Filing Date		February 24, 2004	
First Named Inventor		Summar et al.	
Art Unit		1638	
Examiner Name		D. Johannsen	
Sheet	2	of	2
		Attorney Docket Number	
		1242/58 CIP	

NON-PATENT LITERATURE DOCUMENTS

Examiner Signature	Date Considered	
-----------------------	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This time collection is estimated to take 2 hours to complete, including gathering, preparing, and completing the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time will be considered helpful in evaluating this collection. This collection is being filed to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. OFFICE USE: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.